24.69
전일 마감가:
$24.38
열려 있는:
$24.68
하루 거래량:
3.99M
Relative Volume:
0.40
시가총액:
$10.45B
수익:
$5.06B
순이익/손실:
$-2.22B
주가수익비율:
-4.2421
EPS:
-5.82
순현금흐름:
$-3.96B
1주 성능:
-10.54%
1개월 성능:
-7.39%
6개월 성능:
-47.26%
1년 성능:
-79.87%
모더나 Stock (MRNA) Company Profile
명칭
Moderna Inc
전화
(617) 714-6500
주소
325 BINNEY STREET, CAMBRIDGE
MRNA을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
MRNA
Moderna Inc
|
24.70 | 10.45B | 5.06B | -2.22B | -3.96B | -5.82 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
431.06 | 128.25B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
537.77 | 63.70B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ARGX
Argen X Se Adr
|
545.62 | 39.07B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
252.44 | 33.27B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ONC
Beigene Ltd Adr
|
231.00 | 27.58B | 3.81B | -644.79M | -669.77M | -6.24 |
모더나 Stock (MRNA) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-03-13 | 개시 | Citigroup | Neutral |
2025-02-18 | 다운그레이드 | Barclays | Overweight → Equal Weight |
2025-01-29 | 다운그레이드 | Goldman | Buy → Neutral |
2024-12-18 | 다운그레이드 | Argus | Buy → Hold |
2024-12-10 | 재개 | BofA Securities | Underperform |
2024-11-19 | 개시 | Berenberg | Hold |
2024-11-18 | 업그레이드 | HSBC Securities | Hold → Buy |
2024-11-15 | 개시 | Wolfe Research | Underperform |
2024-10-17 | 개시 | Bernstein | Mkt Perform |
2024-09-13 | 다운그레이드 | JP Morgan | Neutral → Underweight |
2024-09-13 | 다운그레이드 | Jefferies | Buy → Hold |
2024-09-13 | 다운그레이드 | Oppenheimer | Outperform → Perform |
2024-08-28 | 업그레이드 | HSBC Securities | Reduce → Hold |
2024-08-07 | 업그레이드 | Deutsche Bank | Sell → Hold |
2024-08-05 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
2024-02-26 | 다운그레이드 | HSBC Securities | Hold → Reduce |
2024-01-02 | 업그레이드 | Oppenheimer | Perform → Outperform |
2023-11-29 | 개시 | Canaccord Genuity | Hold |
2023-11-03 | 업그레이드 | HSBC Securities | Reduce → Hold |
2023-11-02 | 다운그레이드 | Deutsche Bank | Hold → Sell |
2023-08-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
2023-08-03 | 다운그레이드 | Deutsche Bank | Buy → Hold |
2023-07-24 | 개시 | William Blair | Mkt Perform |
2023-07-14 | 개시 | HSBC Securities | Reduce |
2023-06-26 | 업그레이드 | UBS | Neutral → Buy |
2023-04-26 | 개시 | Guggenheim | Neutral |
2023-03-13 | 업그레이드 | TD Cowen | Market Perform → Outperform |
2023-03-02 | 개시 | RBC Capital Mkts | Outperform |
2023-02-24 | 다운그레이드 | SVB Securities | Market Perform → Underperform |
2022-12-19 | 업그레이드 | Jefferies | Hold → Buy |
2022-12-14 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
2022-10-21 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
2022-09-08 | 업그레이드 | Deutsche Bank | Hold → Buy |
2022-02-01 | 업그레이드 | Redburn | Sell → Neutral |
2022-01-26 | 업그레이드 | Deutsche Bank | Sell → Hold |
2022-01-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
2022-01-21 | 개시 | UBS | Neutral |
2021-12-07 | 개시 | Cowen | Market Perform |
2021-11-09 | 개시 | Wolfe Research | Outperform |
2021-10-22 | 개시 | Deutsche Bank | Sell |
2021-10-15 | 업그레이드 | Piper Sandler | Neutral → Overweight |
2021-08-06 | 다운그레이드 | Oppenheimer | Outperform → Perform |
2021-08-06 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
2021-07-15 | 재확인 | Jefferies | Hold |
2021-02-01 | 다운그레이드 | BofA Securities | Neutral → Underperform |
2020-12-16 | 다운그레이드 | Jefferies | Buy → Hold |
2020-12-16 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2020-12-09 | 다운그레이드 | Needham | Buy → Hold |
2020-11-23 | 개시 | Wells Fargo | Equal Weight |
2020-11-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
2020-09-08 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
2020-07-23 | 개시 | SVB Leerink | Mkt Perform |
2020-07-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2020-07-13 | 개시 | Jefferies | Buy |
2020-06-30 | 개시 | Argus | Buy |
2020-06-08 | 개시 | Barclays | Overweight |
2020-04-30 | 개시 | BMO Capital Markets | Outperform |
2020-03-05 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
2019-12-03 | 재개 | BofA/Merrill | Buy |
2019-10-25 | 개시 | ROTH Capital | Buy |
2019-04-05 | 개시 | Chardan Capital Markets | Buy |
모두보기
모더나 주식(MRNA)의 최신 뉴스
Moderna study shows immune response in older adults for a combo flu and COVID-19 shot - New Castle News
Collar Capital Management LLC Invests $898,000 in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Banque Transatlantique SA Purchases New Stake in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Axa S.A. Sells 38,456 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
PDT Partners LLC Has $280,000 Stake in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna claims to have combined flu and COVID-19 vaccines - CBS News
Kovitz Investment Group Partners LLC Sells 40,925 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna study shows immune response in older adults for a new combo flu and COVID-19 shot - kotatv.com
Moderna Stock: Analyst Estimates & Ratings - Nasdaq
How effective will Moderna's combo Covid and flu mRNA shot be? - KSNV
Moderna, Inc. (NASDAQ:MRNA) Stake Lifted by Northern Trust Corp - MarketBeat
Moderna (MRNA) and Pfizer/BioNTech Vaccines Under FDA Review - GuruFocus
FDA advisory panel to discuss makeup of updated COVID shots - Seeking Alpha
MRNA Sees Surge in Options Activity with Notable Imbalance | MRNA Stock News - GuruFocus
June 27th Options Now Available For Moderna (MRNA) - Nasdaq
Moderna's Combo Flu and COVID Shot Shows Promise - El Paso Inc.
197,500 Shares in Moderna, Inc. (NASDAQ:MRNA) Bought by Cutter Capital Management LP - MarketBeat
Moderna to Present at Upcoming Bernstein's 41st Annual Strategic Decisions Conference (SDC) on May 29, 2025 | MRNA Stock News - GuruFocus
Moderna to Present at Upcoming Bernstein's 41st Annual Strategic Decisions Conference (SDC) on May 29, 2025 - The Derrick
RFK Jr. Takes Aim at Covid Shots for Kids, Worrying Vaccine Experts - Bloomberg
Combo flu and COVID-19 shot shows promise in new Moderna study - LiveNOW from FOX
US FDA advisers to discuss COVID-19 vaccine recommendations on May 22 - marketscreener.com
Moderna Vaccine Study - Tulsa World
Cantor Fitzgerald L. P. Purchases New Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Dimensional Fund Advisors LP Has $69.34 Million Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
BLI Banque de Luxembourg Investments Takes Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
GraniteShares adjusts Moderna ETP in upcoming consolidation By Investing.com - Investing.com UK
This Week's Healthcare Earnings: Moderna, CVS, Hims & Hers - Law360
Moderna, Pharma Stocks Fall as FDA Names Industry Critic as Top Vaccine Regulator - Barron's
Moderna Sharpens Pipeline Focus as COVID-19 Vaccine Demand Ebbs in Q1 - The Globe and Mail
Redburn Atlantic Adjusts Moderna Price Target to $53 From $52, Maintains Neutral Rating - marketscreener.com
Public Employees Retirement Association of Colorado Trims Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
mRNA Vaccines: Evolving Pipelines Across Infectious Disease, Oncology & Rare Disorders - openPR.com
Moderna, Inc. (NASDAQ:MRNA) Stock Position Increased by Lido Advisors LLC - MarketBeat
Price T Rowe Associates Inc. MD Has $44.62 Million Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Envestnet Asset Management Inc. Lowers Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
On the Move: Moderna's Cronin Moves to Medtronic Diabetes - O'Dwyer's PR
Ex-Moderna brand chief Kate Cronin joins Medtronic Diabetes as marketing lead - Medical Marketing and Media
Moderna Sharpens Pipeline Focus As COVID-19 Vaccine Demand Ebbs In Q1 - Barchart.com
The Manufacturers Life Insurance Company Acquires 267,990 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna Stock Crumbles As Vaccine Troubles Rattle Its Topline - MSN
Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Pinebridge Investments L.P. - MarketBeat
Moderna Q1 Earnings Ahead: Analysts expect loss amid increased regulatory scrutiny - MSN
Moderna, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – MRNA - ACCESS Newswire
Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Aquatic Capital Management LLC - MarketBeat
UBS Analyst Lowers Price Target for MRNA, Maintains Buy Rating | - GuruFocus
XTX Topco Ltd Decreases Stock Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Barclays Lowers Price Target on Moderna (MRNA) to $40.00 | MRNA Stock News - GuruFocus
모더나 (MRNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
모더나 주식 (MRNA) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
SAGAN PAUL | Director |
Mar 03 '25 |
Buy |
31.76 |
31,620 |
1,004,251 |
312,027 |
Klinger Shannon Thyme | Chief Legal Officer |
Dec 09 '24 |
Sale |
44.68 |
529 |
23,637 |
20,446 |
자본화:
|
볼륨(24시간):